Abecasis João, Dores Helder, Arroja Isarel, Santos José Miguel, Silva Aniceto
Serviço de Cardiologia, Hospital de São Francisco Xavier-CHLO, Lisboa, Portugal.
Rev Port Cardiol. 2009 Oct;28(10):1153-9.
Classic antimalarial drugs, particularly quinine and its derivatives, are well known for their potential pro-arrhythmic effects. Recently developed synthetic antimalarials are widely used among travelers for prophylaxis. Nevertheless, their safety is open to question, especially for travelers under common cardiovascular drug therapy. We report the case of a patient admitted for symptomatic high-grade atrioventricular (AV) block, caused by combined therapy with a common malaria prophylactic drug--mefloquine--and a beta-blocker prescribed for a symptomatic arrhythmia. Withdrawal of the beta-blocker led to disappearance of the AV block despite continuation of the malaria prophylaxis. Mefloquine drug interactions are briefly described, particularly in terms of the caution needed in travelers already under beta-blocker therapy in whom antimalarial drug prophylaxis is recommended.
经典抗疟药物，尤其是奎宁及其衍生物，因其潜在的促心律失常作用而广为人知。最近研发的合成抗疟药物在旅行者中广泛用于预防。然而，其安全性存在疑问，尤其是对于正在接受普通心血管药物治疗的旅行者。我们报告了一例因联合使用一种常见的疟疾预防药物——甲氟喹，以及为治疗症状性心律失常而开具的β受体阻滞剂导致症状性高度房室传导阻滞而入院的患者。停用β受体阻滞剂后，尽管继续进行疟疾预防，房室传导阻滞仍消失。本文简要描述了甲氟喹的药物相互作用，特别是对于已接受β受体阻滞剂治疗且建议进行抗疟药物预防的旅行者需要谨慎的方面。
